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Introduction
In a recent review article of the causes of community-acquired 
pneumonia (CAP) in adults, Musher et al. reported that S. 
aureus is now the third most common bacterial pathogen 
causing CAP [1]. Physicians treating patients with CAP will be 
confronted with the question of how best to treat a hospitalized 
patient with bacteremic S. aureus CAP. In this opinion piece, we 
will review current controversies on the topic and offer our point 
of view regarding management and treatment. 
Controversies
1. Can patients with bacteremic S. aureus CAP be 
treated with short course antibiotic therapy?
Patients with bacteremic S. aureus CAP should not be treated 
with short courses of antibiotics.
A substantial proportion of patients hospitalized with 
community-acquired pneumonia (CAP) will reach clinical 
stability after 3 days of initiation of antibiotic therapy. In these 
patients, guideline recommendations advocate that intravenous 
antibiotics can be switched to oral to complete 5 to 7 days of 
total antibiotic therapy [2].  An important exception to the early 
switch and short duration of therapy approach is for patients 
with CAP due to S. aureus who are also found to be bacteremic. 
In these patients, we recommend a duration of therapy of at 
least 2 weeks. For such patients, duration of therapy should 
be addressed from the perspective of the bacteremia and not 
from the perspective of the pneumonia. From the pneumonia 
perspective, the patient may have a significant improvement 
of signs and symptoms of CAP and may reach early clinical 
stability, but in the clinical scenario of S. aureus bacteremia, 
the clinical improvement of pulmonary infection is no longer 
a marker to define duration of therapy. The number of days 
of antibiotic therapy should be based on the evaluation and 
management of S. aureus bacteremia, according to the presence 
of uncomplicated versus complicated bacteremia [3-5].
2. What should be the duration of treatment for 
patients with bacteremic S. aureus CAP? 
Patients with uncomplicated bacteremic S. aureus CAP should 
be treated with at least 2 weeks of antibiotics.
Patients with complicated bacteremic S. aureus CAP should be 
treated with 4 to 6 weeks of antibiotics.
All patients with S. aureus bacteremia are at risk of developing 
metastatic infections. Some of these infections may not be clin-
ically evident at the time the patient presents with bacteremia, 
such as endovascular infections (e.g. endocarditis), bone and 
joint infections (e.g. vertebral osteomyelitis) or nervous system 
infections (e.g. spinal epidural abscess). According to the level of 
risk of metastatic infections, bacteremia is categorized as a low 
risk or uncomplicated versus high risk or complicated. 
For a bacteremic S. aureus CAP to be considered uncomplicat-
ed: there should be a rapid clinical response to initial antibiotic 
therapy, (e.g. temperature <100.50 F within 3 days); an echo-
cardiogram should be negative; the patient should not have any 
prosthetic material (e.g. prosthetic joint); the patient should 
not be immunocompromised; and the bacteremia should be 
non-persistent (see below). If all these characteristics are pres-
ent, the patient is considered to be at low risk of metastatic in-
fection. Treatment in these patients is still recommended for a 
total 2 weeks to treat the possible presence of an early and un-
recognized metastatic infection [3-5] (Figure 1). 
Bacteremic S. aureus CAP is considered to be complicated if: 
there is a poor clinical response to initial antibiotic therapy, (e.g. 
temperature >100.50 F for more than 3 days); echocardiogram 
suggests the presence of a vegetation on a heart valve or 
a valvular abnormality which is a risk for endocarditis; a 
prosthetic material (e.g. prosthetic joint) is present, the patient 
is immunocompromised; or the bacteremia is persistent (see 
below). If any of these characteristics are present, the patient is 
considered to be at high risk of metastatic infection, even if no 
specific site is identified. The recommended duration of therapy 
in these patients is 4 to 6 weeks of intravenous therapy with an 
appropriate antimicrobial agent based on susceptibility data 
[3-5] (Figure 1). There are not prospective studies to define 
best duration of therapy within the 4 to 6 weeks recommended 
in patients with complicated bacteremia. We suggest that 
duration of therapy can be individualized. Patients with rapid 
improvement and negative repeat blood cultures may need only 
4 weeks of therapy. 
Figure 1. Duration of therapy for S. aureus bacteremia (for definitions of 
non-persistent and persistent bacteremia see text).
3. How to diagnose persistent S. aureus bacteremia 
in a patient with CAP?
Patients hospitalized at risk of S. aureus bacteremia should 
have 2 sets of blood cultures obtained at least 30 minutes apart.
In a patient with CAP due to S. aureus, bacteria from the alveoli 
can traverse lymph nodes, and be transported via lymphatic 
vessels into subclavian veins. After S. aureus enter the blood, 
bacteria are removed from the circulation within 10-20 minutes, 
primarily by macrophages in the spleen and the liver. Patients 
with S. aureus endocarditis have continuous or persistent 
bacteremia, where as those who have an in infection in another 
site, such as the lung, the kidney or soft tissue, are more likely 
to have intermittent or non-persistent bacteremia. Patients with 
non-persistent S. aureus bacteremia are still at risk of developing 
metastatic infections, since only minutes of S. aureus in the 
systemic circulation may be enough for the bacteria to attach to 
deep tissues. If after an initial bacteremia, S. aureus is able to 
establish a metastatic intravascular infection (e.g. endocarditis) 
then the presence of bacteria in the systemic circulation will be 
constant. Even though macrophages from the spleen and liver 
will continue to remove bacteria from the blood, the continuous 
arrival of bacteria to the systemic circulation will allow the 
bacteria to persist in the systemic circulation for long periods of 
time. This will produce a persistent type of bacteremia. 
When we use blood cultures as diagnostic tests, there are several 
questions that we attempt to answer. First, we need to determine 
whether bacteremia is present. To answer this question, it is 
necessary to have enough blood in the laboratory, because an 
adequate volume sampling is an important factor for detection 
of bacteremia. Approximately 8 to 10 mL of blood are obtained 
with each set of 2 blood culture bottles, the order of 2 sets will 
allow 15 to 20 mL of blood to be cultured. Second, we need to 
determine whether the bacteria identified in the culture bottle 
represent a skin contaminant. To answer this second question, it 
is necessary to obtain each set of blood cultures from a different 
skin sites. Third, we need to define if persistent bacteremia is 
present. To answer this third question, we need to separate 
the timing of each of the blood cultures.  As explained before, 
in a non-persistent bacteremia, bacteria may be present in the 
blood from 10 to 20 minutes. Blood cultures obtained with a 
time separation under 20 minutes will not be enough to define 
is the patient is having a persistent bacteremia. In an attempt 
to answer the question regarding persistent bacteremia, blood 
cultures should be obtained at least 30 minutes apart [6]. 
Patients with multiple positive blood cultures for S. aureus 
are more likely to have endocarditis, but persistently positive 
cultures may be present in patients with infections other than 
endocarditis [7,8].  Documentation of persistently positive blood 
cultures for S. aureus is a major Duke criteria for diagnosis 
of endocarditis [9]. To fulfill this criterion, cultures should be 
positive from 2 blood cultures drawn 12 hours apart, or from all 
of 3 blood cultures, with first and last drawn at least 1 hour apart 
[9]. We consider that all hospitalized patients with CAP should 
have 2 sets of blood cultures obtained, but the timing of the 
blood cultures is controversial since separating blood cultures 
beyond 30 minutes may create logistical problems and delay 
antibiotic therapy.
4. Should an Echocardiogram be obtained in all 
patients with bacteremic S. aureus CAP?
All patients with bacteremic S. aureus CAP should have an 
echocardiogram performed to evaluate for the presence of 
endocarditis. 
Patients with S. aureus in the blood are considered at risk of 
infective endocarditis. At the present time S. aureus is the 
primary etiologic agent of endocarditis in industrialized countries 
[10]. There is agreement in the need for echocardiogram in 
all patients with S. aureus bacteremia without a clear source 
of bacteremia. This scenario does not apply to patients with 
CAP, in whom the source of bacteremia is the lung. There is 
also agreement in the need for echocardiogram in patients with 
evidence of complicated bacteremia. The disagreement is with 
patients with uncomplicated bacteremia. Do we need to perform 
an evaluation for endocarditis in a patient with CAP, who is not 
immunocompromised, with no prosthesis, with good initial 
response to therapy, and with only one out of two positive blood 
cultures? Even though in these patients the risk for endocarditis 
is low, in our opinion, all hospitalized patients with bacteremic 
S. aureus CAP should have an echocardiogram. In patients 
with uncomplicated bacteremia, who are at a very low risk for 
endocarditis, a negative transthoracic echocardiogram (TTE) 
may be enough to decide duration of therapy, without the need 
of a subsequent transesophageal echocardiogram (TEE). A TTE 
is readily available, of relative low cost, and with no risk for 
the patient. Patients with complicated bacteremia are at high 
risk for endocarditis. In these patients, a negative TTE should 
be followed with a TEE, since TEE is a more sensitive test for 
diagnosis of endocarditis.
5. When do we start counting the duration of therapy 
in patients with bacteremic S. aureus CAP?
Duration of therapy is counted from the day that the first 
negative blood culture is obtained. 
Duration of therapy in patients with pneumonia is counted from 
the day that initial appropriate empiric therapy was initiated. In 
the case of S. aureus bacteremia, duration of therapy is counted 
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from the day of first negative blood culture. All patients with S. 
aureus bacteremia should have repeat blood cultures every 48 
to 72 hours until blood cultures are negative. The first day of 
negative blood culture is the first day of duration of therapy.
6. Can we switch from intravenous to oral therapy in 
patients with bacteremic S. aureus CAP?
In patients with uncomplicated bacteremic S. aureus CAP, 
intravenous antibiotic therapy may be switched to oral 
antibiotic therapy.
Patients with complicated bacteremic S. aureus CAP should be 
treated only with intravenous therapy.
For the treatment of patients with S. aureus bacteremia we 
generally prefer therapy with intravenous antibiotics. A switch 
from intravenous to oral therapy should be done cautiously 
and only in special circumstances since there are no studies 
of oral therapy in these patients. An example may be a patient 
hospitalized with CAP and uncomplicated S. aureus bacteremia. 
The repeat blood cultures are negative, the patient is clinically 
stable, and ready to be discharged from the hospital to complete 
the 2 weeks of therapy at home. In these patients, the benefit 
of intravenous therapy for a short duration should be balanced 
against the risk of a IV line and cost of home IV antibiotics. 
In this clinical scenario, we consider that patients may be 
switched to an oral antibiotic that has good susceptibility and 
good oral absorption and to which the organism is susceptible. 
Virtually all available studies of treatment for complicated S. 
aureus bacteremia have been based on patients who have been 
treated parenterally. We base our recommendation on this 
body of medical literature.  That being said, if a patient refuses 
intravenous therapy for 4-6 weeks or cannot afford it, an oral 
agent that is known to be bioavailable can be used instead.  
Conclusions
In treating patients hospitalized for CAP, antibiotics are 
generally given parenterally until he patient is clinically stable, 
after which oral antibiotics are prescribed, the total duration 
not to exceed 7 days. The exception to this rule is CAP due to S. 
aureus with associated bacteremia. In these patients, treatment 
should address the bacteremia, not the pneumonia, and the 
duration of antibiotic therapy should be determine by whether 
the bacteremia is regarded as complicated or uncomplicated. 
Echocardiogram is recommended in all patients. Minimal 
duration of therapy is two weeks, for patients with 
uncomplicated bacteremia. Duration of therapy for patients for 
complicated bacteremia should be 4 to 6 weeks. The preferred 
route of therapy is intravenous, but a switch to oral therapy may 
be considered in special circumstances.
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